CD3×5T4 In Vitro Activation and Cytotoxicity QSP
Reference paper ↗Fixed-effect in vitro model linking CD3×5T4 immune-synapse formation to T-cell activation, differentiation, and delayed tumor-cell killing.
- Therapeutic
- DuoBody-CD3x5T4, bsIgG1-CD3x5T4
- Modality
- Bispecific antibody / T-cell engager
- Target
- CD3, 5T4
- Disease
- In vitro solid-tumor cell-line assay (not disease-specific)
- Model type
- QSP, TCE/BsAb
Complete model workspace
Checking workspace access…
- Parameters
- 33
- States
- 17
- Equations
- 17
- Derived outputs
- 18
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
MDA-MB-468 untreated, E:T 4:1
Null-control culture with 16,000 tumor cells and 64,000 resting T cells, matching the referenced assay setup.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–72 hour; step 1
| Input | Default | Available range |
|---|---|---|
| CD3-arm 3D dissociation constant | 683 nM | 341.5–1,025 nM |
| Trimer threshold for half-maximal activation | 2.13 molecule/cell | 1.065–3.195 molecule/cell |
| Maximum T-cell activation rate | 0.0106 1/hr | 0.0053–0.0159 1/hr |
| Aggregate trimer threshold for half-maximal killing | 7,098 molecule | 3,549–1.06e+4 molecule |
| Maximum per-effector tumor killing rate | 1.30e-5 1/(hour*cell) | 6.50e-6–1.95e-5 1/(hour*cell) |
Expected readouts
Immune-synapse trimers per T cell (trimers/T cell) · Activated or effector T cells (%) · Effector T cells (cells/well) · Tumor-cell cytotoxicity (%) · Viable and apoptotic tumor cells (cells/well)
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 33 declared model parameters.
More key parameters (1)
How the model represents the biology
Links per-cell CD3×5T4 trimer formation to resting-to-activated-to-effector T-cell dynamics and three-stage apoptotic tumor-cell loss across drug affinity, concentration, antigen density, and effector-to-target ratio.
Related models
Research use only — not for patient-specific prediction or dosing advice.